A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...
Please provide your email address to receive an email when new articles are posted on . Patients with constipation-predominant irritable bowel syndrome treated with a ...
The phase 3 trial included patients 6 to 17 years of age who fulfilled modified Rome III Criteria for child/adolescent functional constipation. Treatment with linaclotide improved the frequency of ...
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving ...
The FDA approved linaclotide (Linzess) capsules to treat irritable bowel syndrome with constipation (IBS-C) in children age 7 years and older, the agency announced Wednesday. The decision makes the ...
(HealthDay News) – Over 26 weeks of treatment, the peptide guanylate cyclase-C agonist linaclotide significantly improves abdominal pain and bowel symptoms in patients with irritable bowel syndrome ...
— Top-line Results Show Trial Met All Primary and Secondary Endpoints — CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE ...
August 30, 2012 — The US Food and Drug Administration (FDA) approved the drug linaclotide (Linzess, Ironwood Pharmaceuticals) today for the treatment of chronic idiopathic constipation and irritable ...
Tokyo’s Astellas Pharma and Cambridge, Mass.-based Ironwood Pharmaceuticals announced positive top-line results from their combined phase III trial for chronic constipation drug linaclotide. Here’s ...
-- Agreement Also Returns to Allergan Rights to LINZESS® (linaclotide) in Mexico -- DUBLIN and CAMBRIDGE, Mass., Oct. 27, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical ...
Review the side-effects of Linaclotide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Two colonic release formulations of linaclotide showed improved abdominal pain relief in patients with irritable bowel syndrome, while one of them also showed improvement in bowel habits in a phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback